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ABSTRACT
Introduction: Previous research has
demonstrated a correlation among patient
preferences, dosing burden, and medication
nonadherence, a well-recognized challenge in
type 2 diabetes mellitus (T2DM). The objective
of this study was to elicit preferences for
alternative dosing regimens for oral
antihyperglycemic therapies among patients
with T2DM and to quantify differences in
dosing preferences among patients with
different characteristics.
Methods: Preferences for dosing of oral
antihyperglycemic drugs (OAD) were evaluated
by surveying patients with T2DM in the United
States (US). Survey participants were adult US
patients with T2DM who were taking no or only
1 OAD and no injectable therapies. Each patient
completed a web-enabled discrete-choice
experiment (DCE) including a series of 8 pairs
of hypothetical OAD profiles. Each profile was
defined by reductions in average glucose,
dosing schedule (e.g., once-weekly, once-daily,
or twice-daily dosing), chance of mild-to-
moderate gastrointestinal side effects,
frequency of hypoglycemia, weight change,
incremental risk of congestive heart failure,
and cost. Each participant also answered a
direct question about dosing preference.
Random-parameters logit was used to analyze
the DCE data. Prespecified subgroups were
analyzed.
Results: Of 2,262 patients invited to
participate, 923 were included in the analysis
(mean age 63 years, 45% male, 79% white).
Reducing dosing frequency was statistically
significantly important to patients; however, it
was relatively less important than medication
cost or clinical outcomes. On average, patients
preferred once-weekly to once-daily dosing.
Patients not currently taking an OAD had a
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stronger preference for once-weekly dosing than
patients on treatment (P = 0.012). Patients
younger than 45 years had a stronger
preference for weekly dosing than older
patients (P\0.075).
Conclusions: For younger patients and patients
not currently on treatment, once-weekly dosing
may provide additional incentive to initiate and
adhere to antihyperglycemic treatment;
however, additional research will be required
to confirm this hypothesis.
Keywords: Conjoint analysis; Discrete-choice
experiment; Patient preferences; Treatment
adherence; Type 2 diabetes mellitus
INTRODUCTION
Previous research has demonstrated a
correlation between dosing burden and
medication nonadherence [1–3]. In type 2
diabetes mellitus (T2DM), therapies including
combinations of oral antihyperglycemic drugs
(OADs) can result in high nonadherence [4].
However, poor adherence to oral antidiabetes
therapies is not limited to combination
therapies and is common among patients just
starting monotherapy [5]. A number of studies
have demonstrated that patients with T2DM are
willing to forgo the benefits of treatment to
reduce treatment burden [6] and have identified
a relationship between patients’ preferences and
likely medication adherence [7, 8]. Other
studies have suggested that less frequent
dosing may result in greater patient
adherence, improved treatment outcomes, and
reduced health care costs [9–12].
Discrete-choice experiments (DCEs), also
known as choice-format conjoint analysis
studies, increasingly have been used to
determine the tradeoffs that patients are
willing to make among features of medical
interventions [13–15]. This method is based on
the premise that medical interventions are
composed of a set of attributes or outcomes,
that the attractiveness of a particular
intervention to an individual is a function of
these attributes, and that choices among
alternatives reveal patients’ relative preferences
for these attributes [16]. A recent study
demonstrated that patients with T2DM have
preferences for reducing the dosing burden of
combination OAD therapy and that patients
with lower current overall medication burden
were more likely to indicate that decreases in
dosing burden would result in an improvement
in their expected medication adherence [7]. The
objective of the current study was to elicit
preferences for alternative dosing regimens for
OAD therapies among patients with T2DM and
to quantify differences in dosing preferences
among patients with different characteristics.
METHODS
Study Sample
Patients were recruited from a probability-
based, nationally representative panel of
United States (US) households maintained by
Knowledge Networks (Palo Alto, CA, USA). To
qualify for inclusion in this study, patients had
to (1) be aged 18 years or older; (2) have a self-
reported physician diagnosis of T2DM; (3) be
currently taking one OAD or no OAD to treat
their T2DM; and (4) be not currently taking
injectable T2DM treatments (e.g., insulin and
glucagon-like-1 receptor agonist). Email
invitations were sent to potential panelists
based on self-reported physician diagnosis of
T2DM. The sample was stratified by age (18–44,
45–64, C65 years), time since diagnosis (B3,
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[3 years), and treatment status (no current
OAD, one current OAD).
Survey Instrument
The online DCE survey was adapted from a
survey used in a previous study [7] and
developed using good research practices [13].
The survey included a series of eight choice
questions; each question presented a pair of
hypothetical, but realistic, OAD medication
profiles (Fig. 1). Patients were asked to choose
their preferred medication profile in each pair.
Each profile was defined by five clinical
outcomes, dosing schedule, and out-of-pocket
cost. Clinical outcomes included reduction in
average glucose (AG) [17] (between 20 and
66 mg/dL) from a baseline of 206 mg/dL,
chance of mild-to-moderate gastrointestinal
side effects (between 10% and 30%), frequency
of hypoglycemia (between none and[2
hypoglycemic episodes per month), weight
Fig. 1 Example of a choice question in the discrete-choice experiment. CHF congestive heart failure
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change within the first 6 months after starting
treatment (between 6 lb weight gain and 6 lb
weight loss), and incremental treatment-related
risk of congestive heart failure (CHF) (between
0% and 3%). The combination of attributes in
each medication profile and the pairing of
profiles in each choice question were
determined by an experimental design with
known statistical properties developed using
good research practices [18].
Relevant clinical attributes and dosing
options were identified based on a review of
clinical literature, product labels, and ongoing
clinical trials in the public domain for OADs,
and in consultation with clinical experts [7].
The ranges of the attribute levels were chosen
to encompass the range of outcome levels
described in the clinical trials literature, as
well as the range over which patients were
willing to accept tradeoffs [7]. The dosing
attribute included three levels (one pill once
daily, two pills once daily, and one pill twice
daily) based on available starting doses for
common OADs prescribed to patients just
starting monotherapy. The dosing attribute
also included a once-weekly level to account
for the future possibility of a once-weekly
dipeptidyl peptidase-4 (DDP-4) inhibitor
(ClinicalTrials.gov Identifier NCT01814748).
Levels of out-of-pocket cost ranged from $0
per month to $200 per month and spanned
the range over which the majority of patients
were willing to trade among cost and other
attributes in pretest interviews. The validity of
the survey instrument was evaluated during
14 face-to-face qualitative pretest interviews
with a convenience sample of patients with
T2DM.
Following the choice questions, each
patient was presented with a direct question
about dosing preference (Fig. 2). Specifically,
each patient was asked to indicate his or her
preferred dosing schedule from four possible
dosing schedules, assuming all other
treatment characteristics were constant across
alternatives.
The survey also collected data on
demographic characteristics, health history,
and treatment experience. The study and
survey design were approved by Research
Triangle Institute’s Office of Research
Protection and Ethics. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. All patients were
required to provide informed consent before
completing the survey. A copy of the survey
instrument is available from the corresponding
author upon request.
Statistical Analysis
The medication choice data were analyzed
using a random-parameters logit model with
NLOGIT 4.0 (Econometric Software, Inc,
Plainview, NY, USA). Random-parameters logit
controls for unobserved preference
heterogeneity among respondents by
estimating a distribution for each preference
parameter [19, 20]. The resulting parameter
estimates can be interpreted as relative
preference weights. The difference between the
relative preference weights on the best and
worst levels of the attribute is the relative
importance of each attribute over the range of
levels included in the survey.
The proportion of patients who preferred
once-weekly dosing over daily-dosing
alternatives was calculated for the overall
sample and for each of the prespecified
subgroups. For each pair of subgroups, P values
(a = 0.05) were calculated using a Chi-squared
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test of the difference between the proportion of
patients who preferred once-weekly dosing and




A total of 2,262 email invitations were sent to
panel members. Of the 940 patients who
responded and consented to participate, 13
patients were excluded from the analysis
because they had no variation in their
responses (i.e., they chose either Medicine A or
Medicine B for every choice question). This
response pattern indicated that the patient was
inattentive to the choice questions. An
additional 4 patients did not complete any of
the choice questions. The final sample included
923 respondents with a mean age of 63 years;
45% of the respondents were male, and 79%
were white. Most respondents (79%) reported
that they were currently using an OAD. Table 1
summarizes the characteristics of the
respondents.
Relative Importance Scores
Relative importance scores are presented in
Fig. 3. The distance between preference
weights for the best level and worst level of an
attribute can be interpreted as the overall
relative importance of the attribute over the
range of levels assessed in the survey. Over the
ranges of levels included in the study, out-of-
pocket cost (between $0 and $200 per month)
was the most important treatment attribute and
was statistically significantly more important
than efficacy, side effects, and dosing.
Reduction in AG was statistically significantly
more important than dosing and the remaining
clinical outcomes. Hypoglycemia, chance of
mild-to-moderate gastrointestinal side effects,
weight change within the first 6 months of
starting treatment, and incremental increase in
the risk of CHF were of approximately equal
importance. Once-weekly dosing was preferred
to one pill once daily. One pill once daily was
preferred to one pill twice daily, which, in turn,
was preferred to two pills once daily. The
difference in preference weights between the
most preferred dosing option (one pill once
Fig. 2 Direct dosing question
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weekly) and one pill once daily was positive and
statistically significant; however, changes in
dosing schedule were relatively less important
than medication cost or changes in clinical
outcomes over the ranges of attribute levels
included in this study.
Dosing Preferences
Patients’ dosing preferences are presented in
Fig. 4. Among all patients, 67% preferred weekly
dosing to any of the daily-dosing schedules.
Among patients not currently taking any OAD,
75% preferred once-weekly dosing to daily-
dosing options. This proportion was
statistically significantly greater (P = 0.012)
than the 65% of patients currently using an
OAD who preferred once-weekly dosing over
daily dosing. Among younger patients
(aged\45 years), 78% preferred once-weekly
dosing to daily dosing; in contrast, 66% of
patients aged 45–64 years (P = 0.065 vs. the
younger age group) and 66% of patients aged
65 years or older (P = 0.074 vs. the younger age
group) preferred once-weekly dosing to daily
dosing, although these findings were not
statistically significant. Similar proportions of
patients whose T2DM was diagnosed within the
previous 3 years and patients whose T2DM was
diagnosed more than 3 years ago preferred
once-weekly dosing to daily dosing: 66% of
patients with a more recent diagnosis preferred
once-weekly dosing, and 67% of patients with a
diagnosis more than 3 years ago preferred once-
weekly dosing.
DISCUSSION
Dosing burden has been found to influence
patients’ expectations about medication
adherence in T2DM [7] and in other chronic
diseases [21]. In this study, we administered a
survey among patients with T2DM to elicit their
preferences among treatment attributes
(including efficacy, tolerability, daily dosing,
and cost) to quantify the relative importance of
reducing OAD dosing burden. Dosing
preferences were elicited using both a DCE
and a direct question.
Many studies have examined patients’
preferences for dosing; however, the results of
these studies are mixed. Some studies find that
patients have statistically significant
preferences for less frequent dosing while
others do not. For example, Hauber et al. [7]





Have health insurancea 95%
Currently being treated with OADs 79%






On treatment (currently taking an OAD) 726






OADs oral antihyperglycemic drugs, T2DM type 2 diabetes
mellitus, SD standard deviation
a Six respondents with missing data
b Seven respondents did not report when they were ﬁrst
diagnosed with T2DM
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found that patients with T2DM had statistically
significant preferences for reducing daily-dosing
frequency, especially among patients with
lower current dosing burdens. Likewise, de
Bekker-Grob et al. [22] found that reducing the
frequency of dosing for osteoporosis
prophylaxis was approximately equally
important as reducing the 10-year risk of
osteoporosis by 10 percentage points among
women in the Netherlands. In contrast, Lancsar
et al. [23] and King et al. [24] found that
preferences for reducing the frequency of daily
dosing of asthma medications were not
statistically significant predictors of treatment
choice among asthma patients in Australia.
Although dosing was less important to
patients with T2DM than clinical outcomes
and cost in this study, patients had strong and
statistically significant preferences for changes
in dosing. In addition, patients had strong and
statistically significant preferences for once-
weekly dosing relative to alternative daily-
dosing regimens. Patients not currently taking
an OAD had stronger preferences for weekly
dosing than did patients who were currently
taking an OAD. A higher proportion of patients
aged 44 years and younger preferred once-
weekly dosing to once-daily dosing when
compared with patients aged 45 years and
older, although this difference was not
statistically significant. The lack of statistical
significance for the difference in preferences for
once-weekly dosing (12 percentage points)
between younger and older patients may be
due to the small sample size in the lower age
group. Time since diagnosis did not have a
Fig. 3 Relative importance scores for attributes in the discrete-choice experiment. The largest relative importance score was
set equal to 10 and all other relative importance scores were calculated relative to the largest relative importance score
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measureable impact on dosing preferences
among the patients in this study.
As all stated-preference studies, this study is
subject to limitations. The results of this study
should be interpreted with these limitations in
mind. First, the survey asked patients to
evaluate hypothetical scenarios. Although this
practice is commonly used for eliciting patient
preferences, the choices indicated by patients
do not have the same impact as actual choices.
In addition, none of the patients in this study
had prior experience with weekly or less
frequent dosing of OADs. Therefore, we
cannot make any definitive statements about
the effect of this type of experience on dosing
preferences. Second, our study implicitly
assumes that all clinical, convenience, and
economic attributes of treatment that are not
included in the DCE are held constant across
the alternatives presented in the choice
questions. In theory, adding these attributes to
the DCE should not change our results;
however, it is unknown whether including
additional attributes in or deleting attributes
from this particular study would yield different
results. Finally, diagnosis of T2DM was self-
reported, and the final sample may not be
representative of the population of patients
with T2DM in the US.
Patients in this study were asked to indicate
which of four possible OAD dosing options they
preferred. Overall, and in each subgroup
evaluated in this study, patients preferred
once-weekly dosing to daily dosing. These
preferences were stronger for younger patients
and patients not currently taking an OAD.
Fig. 4 Proportion of patients preferring weekly dosing to
daily dosing. All proportions are statically signiﬁcantly
different within the overall sample, within the subgroups,
and across the subgroup pairings, except the following
comparisons: respondents aged 18–44 years and respondents
aged 45–64 years (P = 0.065); respondents aged
18–44 years and respondents aged C65 years (P = 0.074);
and respondents whose T2DM was diagnosed B3 years ago
and respondents whose T2DM was diagnosed[3 years ago
(P = 0.864). T2DM type 2 diabetes mellitus
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CONCLUSION
All attributes used to describe T2DM
medications were important to patients. Cost
and glucose control had the greatest impact on
treatment choice, indicating that although
achieving treatment objectives is important to
patients with T2DM, these patients may be
willing to forgo optimal glucose control to
avoid out-of-pocket costs. Dosing, tolerability,
and adverse event risks were relatively less
important than cost and glucose control;
however, these treatment attributes were not
unimportant in treatment choice. The majority
of patients preferred once-weekly dosing to
more frequent dosing. Patients not currently
on treatment and younger patients
(aged\45 years) were more likely to prefer
once-weekly dosing to daily dosing. Therefore,
for younger patients and patients not currently
on treatment, once-weekly dosing may provide
additional incentive to initiate and adhere to
antihyperglycemic treatment. However,
additional research will be required to confirm
this hypothesis.
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